K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · DANAHER CORPORATION
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | DHR | DANAHER CORPORATION | DANAHER CORPORATION | $190K | Issues related to biotechnology, cell and gene therapy General issues related to tariffs Issues related to decarbonization |
| 2026-04-20 | DHR | DANAHER CORPORATION | AKIN GUMP STRAUSS HAUER & FELD | $60K | Issues related to a manufacturing rebate program for domestic production of life sciences products. |
| 2026-04-20 | DHR | DANAHER CORPORATION | FULCRUM PUBLIC AFFAIRS LLC | $50K | Issues Related to biotech and bio manufacturing. |
| 2026-03-26 | DHR | DANAHER CORPORATION | DENTONS US LLP | $0 | |
| 2026-03-04 | DHR | DANAHER CORPORATION | FULCRUM PUBLIC AFFAIRS LLC | $40K | Issues Related to biotech and bio manufacturing. Issues Related to biotech and bio manufacturing. |
| 2026-01-20 | DHR | DANAHER CORPORATION | AKIN GUMP STRAUSS HAUER & FELD | $60K | Issues related to a manufacturing rebate program for domestic production of life sciences products. |
| 2026-01-20 | DHR | DANAHER CORPORATION | FULCRUM PUBLIC AFFAIRS LLC | $50K | Issues Related to biotech and bio manufacturing. |
| 2026-01-19 | DHR | DANAHER CORPORATION | DANAHER CORPORATION | $160K | Issues related to biotechnology, cell and gene therapy General issues related to tariffs |
| 2026-01-13 | DHR | DANAHER CORPORATION | DENTONS US LLP | $0 | |
| 2025-10-20 | DHR | DANAHER CORPORATION | DANAHER CORPORATION | $270K | Issues related to genomic medicines Issues related to biotechnology, cell and gene therapy General issues related to tariffs Discussions regarding export controls |
| 2025-10-20 | DHR | DANAHER CORPORATION | FULCRUM PUBLIC AFFAIRS LLC | $50K | Issues Related to biotech and bio manufacturing. Issues Related to biotech and bio manufacturing. |
| 2025-10-20 | DHR | DANAHER CORPORATION | AKIN GUMP STRAUSS HAUER & FELD | $30K | |
| 2025-10-18 | DHR | DANAHER CORPORATION | AKIN GUMP STRAUSS HAUER & FELD | $0 | Issues related to tariffs on the life sciences industry. |
| 2025-10-15 | DHR | DANAHER CORPORATION | DENTONS US LLP | $60K | Education campaign with policymakers related to life sciences and biotechnology issues. Tax and tariff proposals under review and consideration by Congress and Executive Branch. |
| 2025-10-13 | DHR | DANAHER CORPORATION | MERCURY PUBLIC AFFAIRS, LLC | $70K | Issues related to science & biotechnology products |
| 2025-07-31 | DHR | DANAHER CORPORATION | MERCURY PUBLIC AFFAIRS, LLC | $111K | Issues related to science & biotechnology products |
| 2025-07-21 | DHR | DANAHER CORPORATION | DANAHER CORPORATION | $220K | Issues related to genomic medicines Issues related to biotechnology, cell and gene therapy General issues related to tariffs |
| 2025-07-21 | DHR | DANAHER CORPORATION | FULCRUM PUBLIC AFFAIRS LLC | $40K | Issues Related to biotech and bio manufacturing. Issues Related to biotech and bio manufacturing. |
| 2025-07-17 | DHR | DANAHER CORPORATION | DENTONS US LLP | $70K | Education campaign with policymakers related to life sciences and biotechnology issues. Tax and tariff proposals under review and consideration by Congress and Executive Branch. |
| 2025-04-21 | DHR | DANAHER CORPORATION | DANAHER CORPORATION | $230K | Issues related to genomic medicines Issues related to biotechnology, cell and gene therapy General issues related to tariffs |
| 2025-04-21 | DHR | DANAHER CORPORATION | FULCRUM PUBLIC AFFAIRS LLC | $40K | Issues Related to biotech and bio manufacturing. Issues Related to biotech and bio manufacturing. |
| 2025-04-16 | DHR | DANAHER CORPORATION | MERCURY PUBLIC AFFAIRS, LLC | $50K | Issues related to science & biotechnology products |
| 2025-04-12 | DHR | DANAHER CORPORATION | DENTONS US LLP | $100K | Education campaign with policymakers related to life sciences and biotechnology issues. Tax and tariff proposals under review and consideration by Congress and Executive Branch. |
| 2025-02-27 | DHR | DANAHER CORPORATION | MERCURY PUBLIC AFFAIRS, LLC | $0 | Issues related to life science & biotechnology products |
| 2025-01-21 | DHR | DANAHER CORPORATION | DANAHER CORPORATION | $180K | Discussions regarding National Biotechnology and Biomanufacturing Initiative - Executive Order 14081 Issues related to genomic medicines Issues related to biotechnology, cell and gene therapy General issues related to antitrust laws General issues related to permanent normal trade relations |
| 2025-01-21 | DHR | DANAHER CORPORATION | FULCRUM PUBLIC AFFAIRS LLC | $40K | Issues related to biotechnology, bio manufacturing Issues Related to biotech and bio manufacturing |